Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker

Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women

(2011) Ida J. Hatoum et al.   AMERICAN HEART JOURNAL

Lipoprotein phospholipase A2 in patients with isolated coronary artery ectasia

(2011) Levent Korkmaz et al.   Clinical Research in Cardiology

Increased plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) levels are related to good collateral development in patients with isolated left coronary artery disease

(2011) Cihan Orem et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2 ): a review

(2011) Isis T Silva et al.   Lipids in Health and Disease

Anti-inflammatory therapeutics for the treatment of atherosclerosis

(2011) Israel F. Charo et al.   NATURE REVIEWS DRUG DISCOVERY

Lipoprotein associated phospholipase A2: role in atherosclerosis and utility as a biomarker for cardiovascular risk

(2011) Kenneth J. Colley et al.   EPMA Journal

Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease

(2010) Ida J Hatoum et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Phospholipase A2s: Developing drug targets for atherosclerosis

(2010) Keith Suckling   ATHEROSCLEROSIS

Lp-PLA2: A New Target for Statin Therapy

(2010) Lynne T. Braun et al.   Current Atherosclerosis Reports

Plasma levels of lipoprotein-associated phospholipase A2are increased in patients with β-thalassemia

(2010) Alexandros D. Tselepis et al.   JOURNAL OF LIPID RESEARCH

Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

(2010)   LANCET

Lipoprotein-associated phospholipase A2 (Lp-PLA2) and risk of cardiovascular disease in older adults: Results from the Cardiovascular Health Study

(2009) Nancy Swords Jenny et al.   ATHEROSCLEROSIS

Lipoprotein-Associated Phospholipase A 2 and Risk of Congestive Heart Failure in Older Adults

(2009) Takeki Suzuki et al.   Circulation-Heart Failure

Darapladib and atherosclerotic plaque: Should lipoprotein-associated phospholipase A2 be a therapeutic target?

(2009) Peter A. McCullough   Current Atherosclerosis Reports

Fenofibrate reduces lipoprotein associated phospholipase A 2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome

(2008) Robert S. Rosenson   AMERICAN HEART JOURNAL

Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines

(2008) Michael H. Davidson et al.   AMERICAN JOURNAL OF CARDIOLOGY

Lipoprotein-Associated Phospholipase A2: An Independent Predictor of Coronary Artery Disease Events in Primary and Secondary Prevention

(2008) Jeffrey L. Anderson   AMERICAN JOURNAL OF CARDIOLOGY

Review of the Evidence for the Clinical Utility of Lipoprotein-Associated Phospholipase A2 as a Cardiovascular Risk Marker

(2008) Marshall A. Corson et al.   AMERICAN JOURNAL OF CARDIOLOGY

Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke

(2008) Margaretha Persson et al.   ATHEROSCLEROSIS

Plasma lipoprotein-associated phospholipase A2 levels in heart failure: Association with mortality in the community

(2008) Yariv Gerber et al.   ATHEROSCLEROSIS

Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2)

(2008) Diana M. Stafforini   CARDIOVASCULAR DRUGS AND THERAPY

Effects of the Direct Lipoprotein-Associated Phospholipase A 2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque

(2008) Patrick W. Serruys et al.   CIRCULATION

Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study

(2008) S. Tsimikas et al.   EUROPEAN HEART JOURNAL

Identification of a Domain That Mediates Association of Platelet-activating Factor Acetylhydrolase with High Density Lipoprotein

(2008) Alison A. Gardner et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The emerging roles of PAF acetylhydrolase

(2008) Thomas M. McIntyre et al.   JOURNAL OF LIPID RESEARCH

The LDL modification hypothesis of atherogenesis: an update

(2008) Daniel Steinberg   JOURNAL OF LIPID RESEARCH

The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans

(2008) Bonnie Ky et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipoprotein-Associated Phospholipase A2 Is an Independent Predictor of Incident Coronary Heart Disease in an Apparently Healthy Older Population

(2008) Lori B. Daniels et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Distribution and Correlates of Lipoprotein-Associated Phospholipase A2 in an Elderly Cohort: The Cardiovascular Health Study

(2008) Curt D. Furberg et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

(2008) Robert L Wilensky et al.   NATURE MEDICINE

Enhanced Expression of Lp-PLA 2 and Lysophosphatidylcholine in Symptomatic Carotid Atherosclerotic Plaques

(2008) Dallit Mannheim et al.   STROKE

Lipoprotein-Associated Phospholipase A2 Predicts Progression of Cardiac Allograft Vasculopathy and Increased Risk of Cardiovascular Events in Heart Transplant Patients

(2008) Eugenia Raichlin et al.   TRANSPLANTATION